- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00655161
A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation
January 28, 2014 updated by: GlobeImmune
A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation
This is a consolidation therapy trial evaluating GI-4000 in subjects with NSCLC treated with curative intent who are disease free at their first post-treatment restaging assessment.
Study Overview
Detailed Description
NSCLC is the deadliest form of human cancer, killing approximately 150,000 people a year in the United States.
The best treatment for NSCLC is surgical resection.
For patients with inoperable or unresectable NSCLC chemotherapy and radiation is used as first line therapy.
This is a consolidation therapy trial evaluating GI-4000 in subjects with NSCLC treated with curative intent who are disease free at their first post-treatment restaging assessment.
These subjects must also have a ras mutation.
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- Memorial Sloan-Kettering Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Pathologically proven stage I-III NSCLC
- Confirmed product related ras mutation
- ECOG performance status of less than or equal to 2
- greater than or equal to 18 years of age
Exclusion Criteria:
- History of a previous cancer
- History of splenectomy
- History of Crohns disease or ulcerative colitis
- History of major organ transplantation
- Concurrent or chronic steroid therapy
- History of allergy to yeast
- Presence of an unstable or poorly controlled medical condition
- Pregnant or nursing mothers
- Positive skin test to yeast
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Immune response to GI-4000
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Jamie Chaft, MD, Memorial Sloan Kettering Cancer Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2008
Primary Completion (Actual)
November 1, 2013
Study Completion (Actual)
November 1, 2013
Study Registration Dates
First Submitted
April 2, 2008
First Submitted That Met QC Criteria
April 8, 2008
First Posted (Estimate)
April 9, 2008
Study Record Updates
Last Update Posted (Estimate)
January 29, 2014
Last Update Submitted That Met QC Criteria
January 28, 2014
Last Verified
January 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GI-4000-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NSCLC
-
Shanghai Henlius BiotechCompleted
-
The Netherlands Cancer InstituteEnrolling by invitation
-
Centre Oscar LambretUniversity Hospital, LilleTerminated
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompleted
-
Bio-Thera SolutionsCompleted
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
TYK Medicines, IncRecruiting
-
Radboud University Medical CenterPfizer; ImaginAb, Inc.; University Hospital TuebingenNot yet recruitingNSCLCGermany, Netherlands
-
Beta Pharma, Inc.Completed
Clinical Trials on GI-4000
-
University of PennsylvaniaWithdrawnPancreatic Cancer
-
Maastricht University Medical CenterCompleted
-
Botanix PharmaceuticalsCompletedHyperhidrosisUnited States
-
NestléClinical Nutrition Research Centre, SingaporeCompleted
-
Temple UniversityInternational Life Sciences InstituteCompleted
-
Botanix PharmaceuticalsCompletedHyperhidrosisUnited States
-
Bioventus LLCMcMaster University; Clinical Advances Through Research and Information TranslationTerminatedTibial FracturesUnited States, Canada
-
GI DynamicsCompleted
-
Bioventus LLCTerminatedLumbar Degenerative Disc Disease
-
Ohio State UniversityRecruitingGlucose Metabolism Disorders | Spinal Cord Injuries | Postprandial HypotensionUnited States